Detalhe da pesquisa
1.
First-line therapy with palbociclib in patients with advanced HR+/HER2- breast cancer: The real-life study PALBOSPAIN.
Breast Cancer Res Treat
; 206(2): 317-328, 2024 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-38561577
2.
Open-label randomised phase III trial of vinflunine versus an alkylating agent in patients with heavily pretreated metastatic breast cancer.
Ann Oncol
; 29(4): 881-887, 2018 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29481630
3.
Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study.
Breast Cancer Res Treat
; 151(3): 597-606, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25981896
4.
Use of bevacizumab as a first-line treatment for metastatic breast cancer.
Curr Oncol
; 22(2): e51-60, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25908921
5.
Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2-advanced breast cancer: GEICAM/2014-12 (FLIPPER).
Eur J Cancer
; 161: 26-37, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34902765
6.
Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A.
Nat Commun
; 13(1): 7529, 2022 12 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36477027
7.
Prospective, multicenter study on the economic and clinical impact of gene-expression assays in early-stage breast cancer from a single region: the PREGECAM registry experience.
Clin Transl Oncol
; 22(5): 717-724, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-31300934
8.
Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor-positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials.
Eur J Cancer
; 117: 91-98, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31276981
9.
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain.
Clin Transl Oncol
; 20(6): 753-760, 2018 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-29116433